Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

Employees - 4, CEO - Mr. Christer Rosen, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -1.49, Piotroski Score(max is 10): 2, Working Capital: $1721604, Total Assets: $4962826, Retained Earnings: $-27550996, EBIT: -3146960, Total Liabilities: $1898231, Revenue: $0

AryaFin Target Price - $0.12 - Current Price $ - Analyst Target Price $